Re: Exclusive License Agreement dated February 3, 2003 concerning U.S. Patent No. 6,133,433 (the “Agreement”) between Vical Incorporated (“Vical”) and City of Hope (“COH”)Letter Agreement • January 5th, 2012 • Vical Inc • Biological products, (no disgnostic substances)
This letter agreement (this “Letter Agreement”) confirms the understanding of Vical and COH regarding certain matters relating to the Agreement. Capitalized terms used but not otherwise defined in this Letter Agreement shall have the meanings provided in the Agreement.
Re: Notification to City of HopeVical Inc • January 5th, 2012 • Biological products, (no disgnostic substances)
Reference is made to the U.S. License Agreement dated July 12, 2011 (“U.S. License Agreement”) between Vical Incorporated (“Vical”) and Astellas Pharma Inc. (“Astellas”), which provides for Vical’s grant of the sublicense to Astellas under U.S. Patent No. 6,133,433 (“Subject Patent”), which has been licensed to Vical by City of Hope.
July 5, 2011 CytRx CorporationLetter Agreement • January 5th, 2012 • Vical Inc • Biological products, (no disgnostic substances)
